OTUD7a Accelerates Pathological Cardiac Hypertrophy via TAK1 Activation

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Biochemistry

Background:

• Cardiac hypertrophy is a significant risk factor for heart failure and sudden cardiac death.
• OTUD7a, a deubiquitinizing enzyme, has been implicated as a potential tumor suppressor.
• The role of OTUD7a in cardiac hypertrophy remains largely unexplored.

Purpose of the Study:

• To investigate the role of OTUD7a in the development of cardiac hypertrophy.
• To identify the key downstream effectors of OTUD7a in the context of cardiac hypertrophy.

Main Methods:

• Assessed OTUD7a expression in cardiomyocytes and mouse models of cardiac hypertrophy.
• Utilized cardiac-specific OTUD7a knockout mice and viral vectors for in vivo and in vitro studies.
• Employed RNA-sequencing and interactome analysis to identify OTUD7a targets and mechanisms.

Main Results:

• OTUD7a expression is upregulated in cardiac hypertrophy.
• OTUD7a deficiency alleviated cardiac hypertrophy, while its overexpression exacerbated it.
• TAK1 was identified as a direct target, with OTUD7a inhibiting its ubiquitination and promoting its activation.

Conclusions:

• OTUD7a acts as a novel promoter of pathological cardiac hypertrophy.
• The OTUD7a-TAK1 signaling axis is a critical regulator of cardiac hypertrophy.
• Targeting the OTUD7a-TAK1 interaction presents a promising therapeutic avenue for cardiac hypertrophy and heart failure.